Physicians' Academy for Cardiovascular Education

Clinical benefit of PCSK9 inhibition in diabetic patients on insulin at high CV risk

Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial

Literature - Leiter LA, Cariou B, Müller-Wieland D, et al. - Diabetes Obes Metab. 2017; published online ahead of print

Main results

Conclusion

The PCSK9-antibody alirocumab produced significant LDL-C reductions in individuals with hypercholesterolemia with either T2DM or T1DM at high CV risk receiving insulin treatment, with no apparent effect on overall safety or measures of glycemic control. These data show that the concomitant therapy with alirocumab and insulin is feasible.

References

Show references

Find this article online at Diab Obesity Metab

Share this page with your colleagues and friends: